Pfizer (PFE) Invested Capital (2009 - 2026)
Pfizer (PFE) posted quarterly Invested Capital of $3.9 billion for Q1 2026, down 12.98% year-over-year from $4.5 billion in Q1 2025, and up 23.34% quarter-over-quarter from $3.2 billion in Q4 2025.
Pfizer (PFE) Invested Capital (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Invested Capital for 18 consecutive years, with $3.9 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Invested Capital fell 12.98% year-over-year to $3.9 billion; the TTM figure through Mar 2026 stood at $15.6 billion (down 52.68% YoY), while the FY2025 annual figure was $3.2 billion, down 54.59% from the prior year.
- Invested Capital improved to $3.9 billion in Q1 2026 per PFE's latest filing, from $3.2 billion in the prior quarter.
- Across five years, Invested Capital topped out at $11.9 billion in Q2 2024 and bottomed at $645.0 million in Q2 2022.
- Historically, Invested Capital has averaged $5.7 billion across 5 years, with a median of $4.3 billion in 2025.
- Annual changes were most pronounced in 2022 — Invested Capital sank 85.18% — and 2023, when it jumped 549.3%.
- Pfizer's Invested Capital stood at $2.9 billion in 2022, then jumped by 251.44% to $10.4 billion in 2023, then sank by 32.89% to $6.9 billion in 2024, then sank by 54.59% to $3.2 billion in 2025, then gained by 23.34% to $3.9 billion in 2026.
- Business Quant data shows PFE's Invested Capital at $3.9 billion in Q1 2026, $3.2 billion in Q4 2025, and $4.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 11.69 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 8.34 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 2.83 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 9.59 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 32.24 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 5.45 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 2.41 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 2.70 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -7.25 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 25.45 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 2.70 Bn |
| Mar 29, 2026 | 3.89 Bn |
| Dec 31, 2025 | 3.15 Bn |
| Sep 28, 2025 | 4.30 Bn |
| Jun 29, 2025 | 4.30 Bn |
| Mar 30, 2025 | 4.47 Bn |
| Dec 31, 2024 | 6.95 Bn |
| Sep 29, 2024 | 9.70 Bn |
| Jun 30, 2024 | 11.94 Bn |
| Mar 31, 2024 | 8.23 Bn |
| Dec 31, 2023 | 10.35 Bn |
| Jul 2, 2023 | 3.99 Bn |
| Apr 2, 2023 | 4.19 Bn |
| Dec 31, 2022 | 2.95 Bn |
| Jul 3, 2022 | 5.99 Bn |
| Apr 3, 2022 | 645.00 Mn |
| Dec 31, 2021 | 2.24 Bn |
| Oct 3, 2021 | 3.63 Bn |
| Jul 4, 2021 | 3.89 Bn |
| Apr 4, 2021 | 4.35 Bn |